{"id":54221,"date":"2025-07-30T10:52:17","date_gmt":"2025-07-30T10:52:17","guid":{"rendered":"https:\/\/ibima.eu\/?post_type=project&#038;p=54221"},"modified":"2025-11-25T12:56:22","modified_gmt":"2025-11-25T12:56:22","slug":"de-11","status":"publish","type":"project","link":"https:\/\/ibima.eu\/en\/project\/de-11\/","title":{"rendered":"DE-11"},"content":{"rendered":"\n[et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2023\/04\/FotoWeb-min-1000&#215;500-1.jpg\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb250px||30px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|700|||||||\u00bb header_text_align=\u00bbcenter\u00bb header_text_color=\u00bb#FFFFFF\u00bb header_font_size=\u00bb40px\u00bb header_2_font=\u00bbPoppins|700|||||||\u00bb header_2_text_color=\u00bb#FFFFFF\u00bb header_2_font_size=\u00bb46px\u00bb global_colors_info=\u00bb{}\u00bb]<h1>Neumolog\u00eda<\/h1>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#235b78&#8243; custom_padding=\u00bb30px||30px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb header_3_font=\u00bbPoppins|700|||||||\u00bb header_3_text_color=\u00bb#FFFFFF\u00bb header_3_font_size=\u00bb34px\u00bb global_colors_info=\u00bb{}\u00bb]<h3>Lineas de Investigaci\u00f3n<\/h3>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.24.3&#8243; _module_preset=\u00bbdefault\u00bb background_color=\u00bb#d3d6dd\u00bb custom_margin=\u00bb||||true|false\u00bb custom_margin_tablet=\u00bb||||true|false\u00bb custom_margin_phone=\u00bb||||true|false\u00bb custom_margin_last_edited=\u00bbon|phone\u00bb custom_padding=\u00bb50px||0px||false|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb2&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb70%\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb4_4&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_text _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb text_text_color=\u00bb#235b78&#8243; text_font_size=\u00bb16px\u00bb text_line_height=\u00bb2.1em\u00bb global_colors_info=\u00bb{}\u00bb]<span style=\"color: #43a5d3;\"><strong>01.<\/strong><\/span>Mecanismos inmunol\u00f3gicos y endofenotipos de asma grave.\n<span style=\"color: #43a5d3;\"><strong><\/strong><\/span><span style=\"color: #43a5d3;\"><strong>02.<\/strong><\/span>Impacto pron\u00f3stico del estado nutricional en la progresi\u00f3n de la enfermedad.\n<span style=\"color: #43a5d3;\"><strong><\/strong><\/span><span style=\"color: #43a5d3;\"><strong>03.<\/strong><\/span>Prevalencia y evoluci\u00f3n de la desnutrici\u00f3n y sarcopenia en pacientes con fibrosis pulmonar.\n<span style=\"color: #43a5d3;\"><strong>04.<\/strong><\/span>Efectividad y seguridad de tratamientos biol\u00f3gicos en asma.[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=\u00bb1&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_padding=\u00bb50px||50px||true|false\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_row column_structure=\u00bb2_3,1_3&#8243; use_custom_gutter=\u00bbon\u00bb gutter_width=\u00bb2&#8243; make_equal=\u00bbon\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb90%\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_column type=\u00bb2_3&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_tabs active_tab_background_color=\u00bb#105e7c\u00bb inactive_tab_background_color=\u00bb#41a7d4&#8243; active_tab_text_color=\u00bb#FFFFFF\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb tab_text_color=\u00bb#FFFFFF\u00bb border_color_all=\u00bb#41a7d4&#8243; global_colors_info=\u00bb{}\u00bb][et_pb_tab title=\u00bbProyectos de investigaci\u00f3n\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"54329\"][\/et_pb_section]\n<div id=\"gtx-trans\" style=\"position: absolute; left: 151px; top: -10px;\">\n<div class=\"gtx-trans-icon\"><\/div>\n<\/div>[\/et_pb_tab][et_pb_tab title=\u00bbEstudios cl\u00ednicos\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"54322\"][\/et_pb_section][\/et_pb_tab][et_pb_tab title=\u00bbPublicaciones cient\u00edficas\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"54325\"][\/et_pb_section][\/et_pb_tab][et_pb_tab title=\u00bbOfertas tecnol\u00f3gicas \u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"54332\"][\/et_pb_section][\/et_pb_tab][et_pb_tab title=\u00bbRegistros de propiedad industrial\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_section global_module=\"54334\"][\/et_pb_section][\/et_pb_tab][\/et_pb_tabs][\/et_pb_column][et_pb_column type=\u00bb1_3&#8243; _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb border_width_left=\u00bb1px\u00bb border_color_left=\u00bbrgba(67,165,211,0.32)\u00bb global_colors_info=\u00bb{}\u00bb][et_pb_blurb title=\u00bbMiembros\u00bb use_icon=\u00bbon\u00bb font_icon=\u00bb&#xf0c0;||fa||900&#8243; icon_color=\u00bb#43a5d3&#8243; icon_placement=\u00bbleft\u00bb _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#235b78&#8243; header_font_size=\u00bb22px\u00bb module_alignment=\u00bbcenter\u00bb custom_margin=\u00bb||||false|false\u00bb custom_padding=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blurb][et_pb_divider color=\u00bb#43a5d3&#8243; divider_weight=\u00bb2px\u00bb _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb width=\u00bb70%\u00bb custom_padding=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_divider][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigador Responsable\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.20.4&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blurb title=\u00bbJos\u00e9 Luis Velasco Garrido\u00bb image=\u00bbhttps:\/\/ibima.eu\/wp-content\/uploads\/2025\/07\/Jose-Luis-Velasco-DE11-1.jpg\u00bb icon_placement=\u00bbleft\u00bb image_icon_width=\u00bb71px\u00bb content_max_width=\u00bb558px\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins||||||||\u00bb header_text_color=\u00bb#24a8d7&#8243; body_link_text_color=\u00bb#919191&#8243; custom_padding=\u00bb|80px||80px|false|true\u00bb hover_enabled=\u00bb0&#8243; border_radii_image=\u00bbon|25%|25%|25%|25%\u00bb global_colors_info=\u00bb{}\u00bb alt=\u00bbJos\u00e9 Luis Velasco DE-11&#8243; title_text=\u00bbJos\u00e9 Luis Velasco (DE11) (1)\u00bb sticky_enabled=\u00bb0&#8243;]<p><strong>Correo electr\u00f3nico:<\/strong> <a href=\"mailto:josel.velasco.sspa@juntadeandalucia.es\">josel.velasco.sspa@juntadeandalucia.es<\/a><br \/><a href=\"https:\/\/orcid.org\/signin?client_id=0000-0002-5982-8983&amp;response_type=code&amp;scope=%2Fperson%2Fupdate%20%2Fread-limited%20%2Factivities%2Fupdate&amp;redirect_uri=https:%2F%2Forcid.scopusfeedback.com%2Finward%2Forcid\" target=\"_blank\" rel=\"noopener\"><strong>ORCID<\/strong><\/a><br \/><a href=\"https:\/\/www.scopus.com\/authid\/detail.uri?authorId=6507370879\" target=\"_blank\" rel=\"noopener\"><strong>SCOPUS<\/strong><\/a><\/p>[\/et_pb_blurb][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigador\/a S\u00e9nior\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb2868&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigador\/a Asistencial Colaborador\/a\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb2883&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigadores\/as posdoctorales y\/o junior\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb2863&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbInvestigadores\/as predoctorales y\/o en formaci\u00f3n\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.27.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb2858&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][dsm_icon_list _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb locked=\u00bboff\u00bb global_colors_info=\u00bb{}\u00bb][dsm_icon_list_child text=\u00bbPersonal T\u00e9cnico\u00bb use_icon=\u00bboff\u00bb use_tooltip=\u00bbon\u00bb tooltip_placement=\u00bbtop\u00bb tooltip_background_color=\u00bb#41a7d4&#8243; tooltip_max_width=\u00bb170px\u00bb _builder_version=\u00bb4.24.0&#8243; _module_preset=\u00bbdefault\u00bb text_font=\u00bbPoppins|600|||||||\u00bb text_text_color=\u00bb#105e7c\u00bb text_font_size=\u00bb20px\u00bb tooltip_font=\u00bb||||||||\u00bb tooltip_text_color=\u00bb#FFFFFF\u00bb tooltip_font_size=\u00bb12px\u00bb global_colors_info=\u00bb{}\u00bb]Ser\u00e1 Investigador de este nivel los Investigadores Responsable que lideren un grupo de investigaci\u00f3n del Instituto y sus Co-IR. Esta categor\u00eda puede incluir investigadores muy excepcionales en su disciplina. [\/dsm_icon_list_child][\/dsm_icon_list][dsm_icon_list _builder_version=\u00bb4.23.1&#8243; _module_preset=\u00bbdefault\u00bb custom_margin=\u00bb|||80px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/dsm_icon_list][et_pb_blog posts_number=\u00bb20&#8243; include_categories=\u00bb2848&#8243; show_thumbnail=\u00bboff\u00bb show_content=\u00bbon\u00bb show_author=\u00bboff\u00bb show_date=\u00bboff\u00bb show_categories=\u00bboff\u00bb _builder_version=\u00bb4.27.4&#8243; _module_preset=\u00bbdefault\u00bb header_font=\u00bbPoppins|600|||||||\u00bb header_text_color=\u00bb#41a7d4&#8243; header_font_size=\u00bb16px\u00bb body_text_color=\u00bb#105e7c\u00bb body_font_size=\u00bb12px\u00bb custom_padding=\u00bb|||100px|false|false\u00bb global_colors_info=\u00bb{}\u00bb][\/et_pb_blog][\/et_pb_column][\/et_pb_row][\/et_pb_section]\n","protected":false},"excerpt":{"rendered":"<p>Neumolog\u00edaLineas de Investigaci\u00f3n01.Mecanismos inmunol\u00f3gicos y endofenotipos de asma grave. 02.Impacto pron\u00f3stico del estado nutricional en la progresi\u00f3n de la enfermedad. 03.Prevalencia y evoluci\u00f3n de la desnutrici\u00f3n y sarcopenia en pacientes con fibrosis pulmonar. 04.Efectividad y seguridad de tratamientos biol\u00f3gicos en asma.<div class=\"et_pb_section et_pb_section_1 et_section_regular\" >\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_row et_pb_row_0\">\n\t\t\t\t<div class=\"et_pb_column et_pb_column_4_4 et_pb_column_0  et_pb_css_mix_blend_mode_passthrough et-last-child\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_with_border et_pb_module et_pb_blog_0 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix\">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"et_pb_salvattore_content\" data-columns>\n\t\t\t<article id=\"post-56663\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_0_0 post-56663 post type-post status-publish format-standard hentry category-proyectos category-proyectos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/valoracion-nutricional-de-pacientes-con-fpi\/\">Valoracion nutricional de pacientes con FPI<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Eva Cabrera Cesar &#8211;  &#8211; LOCAL &#8211; Nuemosur &#8211; 2024<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div><div><div class=\"pagination clearfix\">\n\t<div class=\"alignleft\"><\/div>\n\t<div class=\"alignright\"><\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div> <div class=\"et_pb_section et_pb_section_3 et_section_regular\" >\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_row et_pb_row_1\">\n\t\t\t\t<div class=\"et_pb_column et_pb_column_4_4 et_pb_column_1  et_pb_css_mix_blend_mode_passthrough et-last-child\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_with_border et_pb_module et_pb_blog_1 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix\">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"et_pb_salvattore_content\" data-columns>\n\t\t\t<article id=\"post-56374\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_0 post-56374 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/un-ensayo-multicentrico-prospectivo-y-no-intervencionista-que-monitoriza-las-vias-terapeuticas-de-pacientes-con-asma-tratados-con-una-terapia-triple-extrafina-con-un-solo-inhalador-ics-laba-lama-en-u\/\">Un ensayo multic\u00e9ntrico, prospectivo y no intervencionista que monitoriza las v\u00edas terap\u00e9uticas de pacientes con asma tratados con una terapia triple extrafina con un solo inhalador ICS\/LABA\/LAMA en un entorno real y que caracteriza los efectos sobre los resultados relacionados con la salud.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ALICIA PADILLA GALO &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; LEON RESEARCH, S.L<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56297\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_1 post-56297 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/registro-nacional-de-antibioticos-inhalados-en-patologia-cronica-de-la-via-aerea-repair\/\">Registro Nacional de antibi\u00f3ticos inhalados en patolog\u00eda cr\u00f3nica de la v\u00eda a\u00e9rea (REPAIR).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ALICIA PADILLA GALO &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; FUNDACI\u00d3N ESPA\u00d1OLA DEL PULM\u00d3N &#8211; RESPIRA<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56206\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_2 post-56206 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/observational-retrospective-study-to-describe-the-adherence-during-a-longtermfollow-up-of-patients-with-severe-asthma-treated-with-benralizumab-in-a-real-world-setting-in-spain\/\">Observational retrospective study to describe the adherence during a longtermfollow-up of patients with severe asthma treated with benralizumab in a real world setting in Spain<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ALICIA PADILLA GALO &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; EVIDENZE HEALTH ESPA\u00d1A, S.L.U<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56204\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_3 post-56204 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/observational-retrospective-study-to-describe-characteristics-and-evaluate-real-world-outcomes-in-patients-initiating-trixeo-aerosphere-budesonide-glycopyrronium-bromide-formoterol-fumarate-in-spain\/\">Observational REtrospective Study To Describe Characteristics And Evaluate Real-World Outcomes in Patients Initiating TrixEo Aerosphere (budesonide\/glycopyrronium bromide\/formoterol fumarate) in Spain<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56205\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_4 post-56205 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/observational-retrospective-study-to-describe-the-adherence-during-a-long-term-followupof-patients-with-severe-asthma-treated-with-benralizumab-in-a-real-world-setting-in-spain\/\">Observational retrospective study to describe the adherence during a long-term followupof patients with severe asthma treated with benralizumab in a real world setting in Spain<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56203\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_5 post-56203 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/observational-retrospective-study-to-characterize-and-assess-clinical-outcomes-of-patients-receiving-tezepelumab-in-the-framework-of-use-in-special-situations-prior-to-commercialisation-in-spain-est-2\/\">Observational retrospective study To characterize and assess clinical outcomes of patients Receiving tezepelumab in the framework Of use in Special Situations prior to commercialisation in Spain \/ Estudio observacional retrospectivo para caracterizar y evaluar los resultados cl\u00ednicos de pacientes que recibieron tezepelumab en el marco de uso en situaciones especiales antes de la comercializaci\u00f3n en Espa\u00f1a (T-ROSS).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ALICIA PADILLA GALO &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56202\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_6 post-56202 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/observational-retrospective-study-to-characterize-and-assess-clinical-outcomes-of-patients-receiving-tezepelumab-in-the-framework-of-use-in-special-situations-prior-to-commercialisation-in-spain-est\/\">Observational retrospective study To characterize and assess clinical outcomes of patients Receiving tezepelumab in the framework Of use in Special Situations prior to commercialisation in Spain \/ Estudio observacional retrospectivo para caracterizar y evaluar los resultados cl\u00ednicos de pacientes que recibieron tezepelumab en el marco de uso en situaciones especiales antes de la comercializaci\u00f3n en Espa\u00f1a (T-ROSS)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ESTUDIO OBSERVACIONAL CON MEDICAMENTOS &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56196\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_7 post-56196 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/nuevo-estudio-observacional-longitudinal-en-pacientes-con-un-diagnostico-o-sospecha-de-diagnostico-de-asma-y-o-epoc-para-describir-las-caracteristicas-de-los-pacientes-patrones-de-tratamiento-y-car\/\">Nuevo  estudio observacional, longitudinal en pacientes con un diagn\u00f3stico o sospecha de diagn\u00f3stico de asma y\/o EPOC para describir las caracter\u00edsticas de los pacientes, patrones de tratamiento y carga de la enfermedad con el paso del tiempo para identificar fenotipos y endotipos asociados a resultados diferenciales que pueden respaldar el desarrollo futuro de estrategias de tratamiento personalizadas. D2287R00103<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ASTRAZENECA AB<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56194\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_8 post-56194 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/non-interventional-descriptive-cross-sectional-and-unicentric-study-to-describe-the-clinical-management-in-asthmatic-patients-attended-in-the-influential-area-of-hospital-universitario-virgen-de-la\/\">Non-Interventional, descriptive, cross-sectional and unicentric study to describe the clinical management in asthmatic patients attended in the influential area of Hospital Universitario Virgen de la Victoria, M\u00e1laga.C\u00f3digo: 2020<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO POSAUTORIZACION INDEPENDIENTE &#8211; ESTUDIO POSAUTORIZACION INDEPENDIENTE &#8211; FUNDACION PARA LA INVESTIGACION DE MALAGA EN BIOMEDICINA Y SALUD<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56149\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_9 post-56149 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/frecuencia-y-caracteristicas-diferenciales-del-asma-en-el-tabaquismo-asmatab\/\">Frecuencia y caracter\u00edsticas diferenciales del asma en el tabaquismo ASMATAB.<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>EVA BELEN CABRERA CESAR &#8211; ESTUDIO POSAUTORIZACION INDEPENDIENTE &#8211; ESTUDIO POSAUTORIZACION INDEPENDIENTE &#8211; SOCIEDAD ESPA\u00d1OLA DE NEUMOLOG\u00cdA Y CIRUG\u00cdA TOR\u00c1CICA (SEPAR)<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56060\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_10 post-56060 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-observacional-transversal-para-evaluar-la-calidad-de-vida-relacionada-con-la-salud-cvrs-y-la-medida-de-utilidad-en-pacientes-con-asma-grave-no-controlado-en-espana-estudio-utility\/\">Estudio observacional transversal para evaluar la calidad de vida relacionada con la salud (CVRS) y la medida de utilidad en pacientes con asma grave no controlado en Espa\u00f1a. Estudio UTILITY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO NO POSAUTORIZACION &#8211; ESTUDIO NO POSAUTORIZACION &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56059\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_11 post-56059 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-observacional-transversal-para-caracterizar-la-epoc-grave-en-espana-estudio-clave\/\">Estudio observacional transversal para caracterizar la EPOC grave en Espa\u00f1a. Estudio CLAVE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ADKNOMA HEALTH RESEARCH, S.L.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56054\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_12 post-56054 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-observacional-retrospectivo-para-caracterizar-y-evaluar-los-resultados-clinicos-de-los-pacientes-tratados-con-benralizumab-tras-su-autorizacion-de-comercializacion-en-espana-estudio-orbe-ii\/\">Estudio observacional retrospectivo para caracterizar y evaluar los resultados cl\u00ednicos de los pacientes tratados con benralizumab tras su autorizaci\u00f3n de comercializaci\u00f3n en Espa\u00f1a. Estudio ORBE II<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ASTRAZENECA FARMACEUTICA ESPA\u00d1A S.A.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56041\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_13 post-56041 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-observacional-prospectivo-para-evaluar-el-efecto-de-la-triple-terapia-fija-extrafina-en-un-solo-inhalador-sobre-el-control-de-los-sintomas-y-la-adherencia-al-tratamiento-en-pacientes-con-epoc\/\">Estudio observacional prospectivo para evaluar el efecto de la triple terapia fija extrafina en un solo inhalador sobre el control de los s\u00edntomas y la adherencia al tratamiento en pacientes con EPOC moderada o grave en condiciones de pr\u00e1ctica cl\u00ednica habitual. Estudio TRIATHLON (CHI-EPO-2020-01)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; EVIDENZE HEALTH ESPA\u00d1A, S.L.U<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-56014\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_14 post-56014 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-observacional-de-cohortes-de-la-seguridad-posterior-a-la-autorizacion-pas-para-cuantificar-la-incidencia-y-la-seguridad-comparativa-de-eventos-cardiovasculares-y-cerebrovasculares-especifico-2\/\">Estudio observacional de cohortes de la seguridad posterior a la autorizaci\u00f3n (PAS) para cuantificar la incidencia y la seguridad comparativa de eventos cardiovasculares y cerebrovasculares espec\u00edficos en pacientes con EPOC que utilizan la combinaci\u00f3n UMEC\/VI por inhalaci\u00f3n o UMEC por inhalaci\u00f3n en comparaci\u00f3n con tiotropio. (Estudio 201038)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; IQVIA RDS SWITZERLAND SARL<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55941\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_15 post-55941 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-fase-iv-observacional-multinacional-sobre-el-control-de-la-enfermedad-y-los-resultados-notificados-por-los-pacientes-en-tratamiento-con-inhaladores-de-combinacion-a-dosis-fija-para-asma-pers\/\">Estudio fase IV, observacional, multinacional sobre el control de la enfermedad y los resultados notificados por los pacientes en tratamiento con inhaladores de combinaci\u00f3n a dosis fija para asma persistente y EPOC en la pr\u00e1ctica cl\u00ednica habitual (SPRINT). BFS-AS-40087<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; ESTUDIO POSAUTORIZACION COMERCIAL &#8211; TEVA PHARMACEUTICALS EUROPE<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55935\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_16 post-55935 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-fase-iii-multicentrico-aleatorizado-doble-ciego-dosis-cronica-de-grupos-paralelos-y-controlado-con-placebo-para-evaluar-la-eficacia-y-seguridad-de-tozorakimab-en-pacientes-con-enfermedad\/\">Estudio Fase III, multic\u00e9ntrico, aleatorizado, doble ciego, dosis cr\u00f3nica, de grupos paralelos y controlado con placebo para evaluar la eficacia y seguridad de Tozorakimab en pacientes con enfermedad pulmonar obstructiva cr\u00f3nica (EPOC) sintom\u00e1tica y con historial  de exacerbaciones de la EPOC (MIRANDA)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; ASTRAZENECA AB<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55858\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_17 post-55858 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-iiib-multicentrico-con-un-solo-grupo-de-la-eficacia-y-la-seguridad-de-210-mg-de-tezepelumab-administrado-por-via-subcutanea-para-reducir-el-uso-de-corticoesteroides-orales-en-partici\/\">Estudio en fase IIIb multic\u00e9ntrico, con un solo grupo, de la eficacia y la seguridad de 210 mg de tezepelumab administrado por v\u00eda subcut\u00e1nea para reducir el uso de corticoesteroides orales en participantes adultos con asma grave en tratamiento con corticoesteroides inhalados a dosis altas m\u00e1s agonistas beta2 de acci\u00f3n prolongada y corticoesteroides orales a largo plazo (WAYFINDER)<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>ALICIA PADILLA GALO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; ASTRAZENECA AB<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55854\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_18 post-55854 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-iii-multicentrico-aleatorizado-doble-ciego-y-controlado-con-placebo-para-evaluar-la-eficacia-la-seguridad-y-la-tolerabilidad-de-bms-986278-en-participantes-con-fibrosis-pulmonar-pr\/\">Estudio en fase III, multic\u00e9ntrico, aleatorizado, doble ciego y controlado con placebo para evaluar la eficacia, la seguridad y la tolerabilidad de BMS-986278 en participantes con fibrosis pulmonar progresiva<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; BRISTOL -MYERS SQUIBB SERVICES UNLIMITED COMPANY<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-55846\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_1_19 post-55846 post type-post status-publish format-standard hentry category-ensayos-clinicos category-ensayos-clinicos-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/estudio-en-fase-iii-de-52-semanas-aleatorizado-doble-ciego-controlado-con-placebo-de-grupos-paralelos-con-unaextension-abierta-sobre-la-eficacia-y-seguridad-de-blu-5937-en-participantes-adultos-c\/\">Estudio en fase III, de 52 semanas, aleatorizado, doble ciego, controlado con placebo, de grupos paralelos con unaextensi\u00f3n abierta sobre la eficacia y seguridad de BLU-5937 en participantes adultos con tos cr\u00f3nica refractaria, incluida tos cr\u00f3nica inexplicada (CALM-1).<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>JOSE LUIS VELASCO GARRIDO &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; ENSAYO CLINICO CON MEDICAMENTOS &#8211; IQVIA LTD.<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div><div><div class=\"pagination clearfix\">\n\t<div class=\"alignleft\"><a href=\"https:\/\/ibima.eu\/wp-json\/wp\/v2\/project\/54221\/page\/2\/?et_blog\" >&laquo; Older Entries<\/a><\/div>\n\t<div class=\"alignright\"><\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div><div class=\"et_pb_section et_pb_section_5 et_section_regular\" >\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_row et_pb_row_2\">\n\t\t\t\t<div class=\"et_pb_column et_pb_column_4_4 et_pb_column_2  et_pb_css_mix_blend_mode_passthrough et-last-child\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_with_border et_pb_module et_pb_blog_2 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix\">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"et_pb_salvattore_content\" data-columns>\n\t\t\t<article id=\"post-54751\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_0 post-54751 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/prognostic-factors-of-progressive-fibrotic-hypersensitivity-pneumonitis-a-large-retrospective-multicentre-observational-cohort-study-erj-open-research\/\">Prognostic factors of progressive fibrotic hypersensitivity pneumonitis: a large, retrospective, multicentre, observational cohort study &#8211; ERJ OPEN RESEARCH<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Cano-Jimenez, Esteban; Villar Gomez, Ana; Velez Segovia, Eduardo; Aburto Barrenechea, Myriam; Sellares Torres, Jacobo; Francesqui, Joel; Portillo Carroz, Karina; Solis Solis, Alan Jhunior; Acosta Fernandez, Orlando; Llanos Gonzalez, Ana Belen; Bordas-Martinez, Jaume; Cabrera Cesar, Eva; Balcells Vilarnau, Eva; Castillo Villegas, Diego; Reyes Pardessus, Ana; Gonzalez Fernandez, Coral; Garcia Moyano, Marta; Urrutia Gajate, Amaia; Blanco Hortas, Andres; Molina-Molina, Maria &#8211; 2024 &#8211; 10.1183\/23120541.00405-2023<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54754\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_1 post-54754 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/level-of-compliance-with-spanish-guideline-recommendations-in-the-of-asthma-journal-of-asthma-and-allergy\/\">Level of Compliance with Spanish Guideline Recommendations in the of Asthma &#8211; JOURNAL OF ASTHMA AND ALLERGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Jimenez, Lorena Pinel; Mesa, Alvaro Martinez; Alvarez, Esther Sanchez; Garcia, Javier Lopez; Galvez, Ana Aguilar; Marfil, Nuria Reina; Rodriguez, Belen Gomez; Cesar, Eva Cabrera; Garrido, Jose Luis Velasco &#8211; 2024 &#8211; 10.2147\/JAA.S433291<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-51941\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_2 post-51941 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/ia-body-composition-ct-at-t12-in-idiopathic-pulmonary-fibrosis-diagnosing-sarcopenia-and-correlating-with-other-morphofunctional-assessment-techniques-nutrients\/\">IA-Body Composition CT at T12 in Idiopathic Pulmonary Fibrosis: Diagnosing Sarcopenia and Correlating with Other Morphofunctional Assessment Techniques &#8211; NUTRIENTS<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Fernandez-Jimenez, Rocio; Sanmartin-Sanchez, Alicia; Cabrera-Cesar, Eva; Espildora-Hernandez, Francisco; Vegas-Aguilar, Isabel; Amaya-Campos, Maria del Mar; Palmas-Candia, Fiorella Ximena; Claro-Brandner, Maria; Olivares-Alcolea, Josefina; Simon-Frapolli, Victor Jose; Cornejo-Pareja, Isabel; Guirado-Pelaez, Patricia; Vidal-Suarez, Alvaro; Sanchez-Garcia, Ana; Murri, Mora; Garrido-Sanchez, Lourdes; Tinahones, Francisco J.; Velasco-Garrido, Jose Luis; Garcia-Almeida, Jose Manuel &#8211; 2024 &#8211; 10.3390\/nu16172885<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52309\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_3 post-52309 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/rate-of-severe-and-fatal-infections-in-a-cohort-of-patients-with-interstitial-lung-disease-associated-with-rheumatoid-arthritis-a-multicenter-prospective-study-frontiers-in-immunology\/\">Rate of severe and fatal infections in a cohort of patients with interstitial lung disease associated with rheumatoid arthritis: a multicenter prospective study &#8211; FRONTIERS IN IMMUNOLOGY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Mena-Vazquez, Natalia; Redondo-Rodriguez, Rocio; Rojas-Gimenez, Marta; Romero-Barco, Carmen Maria; Fuego-Varela, Clara; Perez-Gomez, Nair; Anon-Onate, Isabel; Castro Perez, Patricia; Garcia-Studer, Aimara; Hidalgo-Conde, Ana; Arnedo Diez de los Rios, Rocio; Cabrera-Cesar, Eva; Velloso-Feijoo, Maria Luisa; Manrique-Arija, Sara; Calvo-Gutierrez, Jerusalem; Gandia-Martinez, Myriam; Morales-Garrido, Pilar; Godoy-Navarrete, Francisco Javier; Mourino-Rodriguez, Coral; Espildora, Francisco; Aguilar-Hurtado, Maria Carmen; Fernandez-Nebro, Antonio &#8211; 2024 &#8211; 10.3389\/fimmu.2024.1341321<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54763\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_4 post-54763 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/comparison-of-the-determinants-of-the-chronic-obstructive-pulmonary-disease-assessment-test-cat-and-the-asthma-control-test-act-in-patients-with-asthma-copd-overlap-journal-of-clinical-medicine\/\">Comparison of the Determinants of the Chronic Obstructive Pulmonary Disease Assessment Test (CAT) and the Asthma Control Test (ACT) in Patients with Asthma-COPD Overlap &#8211; JOURNAL OF CLINICAL MEDICINE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Aljama, Cristina; Granados, Galo; Callejas-Gonzalez, Francisco Javier; Martinez-Rivera, Carlos; Pallares-Sanmartin, Abel; Rodriguez-Pons, Laura; Cabrera-Cesar, Eva; Marquez-Martin, Eduardo; Boldova-Loscertales, Ana; Naval-Sendra, Elsa; Abascal-Bolado, Beatriz; Cabrera-Lopez, Carlos; Miravitlles, Marc; Esquinas, Cristina; Barrecheguren, Miriam &#8211; 2024 &#8211; 10.3390\/jcm13216367<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-52331\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_5 post-52331 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/rectus-femoris-cross-sectional-area-and-timed-up-and-go-test-potential-useful-of-as-a-predictor-of-sarcopenia-and-mortality-in-idiopathic-pulmonary-fibrosis-frontiers-in-nutrition\/\">Rectus femoris cross sectional area and timed up and go test potential useful of as a predictor of sarcopenia and mortality in idiopathic pulmonary fibrosis &#8211; FRONTIERS IN NUTRITION<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Fernandez-Jimenez, Rocio; Cabrera-Cesar, Eva; Sanmartin-Sanchez, Alicia; Sanchez-Garcia, Ana; Espildora-Hernandez, Francisco; Vegas-Aguilar, Isabel; del Mar Amaya-Campos, Maria; Guirado-Pelaez, Patricia; Simon-Frapolli, Victor; Murri, Mora; Garrido-Sanchez, Lourdes; Pinel-Jimenez, Lorena; Cano-Gamonoso, Miguel Benitez; Lopez-Garcia, Javier; Gomez-Rodriguez, Belen; Velasco-Garrido, Jose Luis; Tinahones, Francisco J.; Garcia-Almeida, Jose Manuel &#8211; 2024 &#8211; 10.3389\/fnut.2024.1440402<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54746\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_6 post-54746 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/clinical-practice-guideline-of-spanish-society-of-pneumology-and-thoracic-surgery-separ-on-pharmacological-treatment-of-tobacco-dependence-2023-archivos-de-bronconeumologia\/\">Clinical Practice Guideline of Spanish Society of Pneumology and Thoracic Surgery (SEPAR) on Pharmacological Treatment of Tobacco Dependence 2023 &#8211; ARCHIVOS DE BRONCONEUMOLOGIA<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Rabade-Castedo, Carlos; de Granda-Orive, Jose Ignacio; Riesco-Miranda, Juan Antonio; De Higes-Martinez, Eva; Ramos-Pinedo, Angela; Cabrera-Cesar, Eva; Minana, Jaime Signes-Costa; Rueda, Marcos Garcia; Pastor-Espla, Esther; Jimenez-Ruiz, Carlos A. &#8211; 2023 &#8211; 10.1016\/j.arbres.2023.07.024<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54753\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_7 post-54753 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/frequency-and-characteristics-of-asthma-in-smokers-attending-smoking-cessation-units-in-spain-plos-one\/\">Frequency and characteristics of asthma in smokers attending smoking cessation units in Spain &#8211; PLOS ONE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Riesco, Juan-Antonio; Rabade, Carlos; Signes-Costa, Jaime; Cabrera, Eva; Jimenez, Carlos-A &#8211; 2023 &#8211; 10.1371\/journal.pone.0294587<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-36997\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_8 post-36997 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/achieving-clinical-outcomes-with-benralizumab-in-severe-eosinophilic-asthma-patients-in-a-real-world-setting-orbe-ii-study-respiratory-research\/\">Achieving clinical outcomes with benralizumab in severe eosinophilic asthma patients in a real-world setting: orbe II study &#8211; RESPIRATORY RESEARCH<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Padilla-Galo, Alicia; Carmona, Isabel Moya; Ausin, Pilar; Fernandez, Luis Carazo; Garcia-Moguel, Ismael; Velasco-Garrido, Jose Luis; Andujar-Espinosa, Ruben; Casas-Maldonado, Francisco; Martinez-Moragon, Eva; Rivera, Carlos Martinez; Solsona, Elisabet Vera; Lopez, Fernando Sanchez-Toril; Alonso, Andrea Trisan; Aparicio, Marina Blanco; Valverde-Monge, Marcela; Azcona, Borja Valencia; Cervera, Marta Palop; Nuevo, Javier; Tena, Jesus Sanchez; Resler, Gustavo; Luzon, Elisa; Naon, Alberto Levy &#8211; 2023 &#8211; 10.1186\/s12931-023-02539-7<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-37026\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_9 post-37026 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/analysis-of-comorbidity-in-rheumatoid-arthritis-associated-interstitial-lung-disease-a-nested-case-cohort-study-biomedicine-pharmacotherapy-2\/\">Analysis of comorbidity in rheumatoid arthritis-associated interstitial lung disease: a nested case-cohort study &#8211; BIOMEDICINE &#038; PHARMACOTHERAPY<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Mena-Vazquez, Natalia; Rojas-Gimenez, Marta; Maria Romero-Barco, Carmen; Gandia-Martinez, Myriam; Perez-Gomez, Nair; Javier Godoy-Navarrete, Francisco; Manrique-Arija, Sara; Garcia-Studer, Aimara; Calvo-Gutierrez, Jerusalem; Fuego Varela, Clara; Morales-Garrido, Pilar; Castro Perez, Patricia; Mourino-Rodriguez, Coral; Anon-Onate, Isabel; Espildora, Francisco; Carmen Aguilar-Hurtado, Maria; Redondo, Rocio; Hidalgo Conde, Ana; Diez de los Rios, Rocio Arnedo; Cabrera Cesar, Eva; Luisa Velloso-Feijoo, Maria; Fernandez-Nebro, Antonio &#8211; 2023 &#8211; 10.1016\/j.biopha.2022.114049<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-37628\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_10 post-37628 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/multidisciplinary-approach-of-the-sequelae-one-month-after-hospital-discharge-in-patients-with-severe-bilateral-covid-19-pneumonia-are-there-differences-depending-on-the-respiratory-therapy-used-dur-5\/\">Multidisciplinary approach of the sequelae one month after hospital discharge in patients with severe bilateral COVID-19 pneumonia, are there differences depending on the respiratory therapy used during admission to intensive care? &#8211; MEDICINA INTENSIVA<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Sanchez-Garcia, A. M.; Martinez-Lopez, P.; Gomez-Gonzalez, A. M.; Rodriguez-Capitan, J.; Jimenez-Lopez, R. J.; Almeida, J. M. Garcia; Avanesi-Molina, E.; Zamboschi, N.; Rueda-Molina, C.; Doncel-Abada, V.; Molina-Ramos, A. I.; Cabrera-Cesar, E.; Ben-Abdellatif, I.; Gordillo-Resina, M.; Perez-Mesa, E.; Nieto-Gonzalez, M.; Nuevo-Ortega, P.; Reina-Artacho, C.; Fernandez, P. L. Sanchez; Jimenez-Navarro, M. F.; Estecha-Foncea, M. A. &#8211; 2023 &#8211; 10.1016\/j.medin.2022.11.002<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-37754\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_11 post-37754 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/post-intensive-care-unit-multidisciplinary-approach-in-patients-with-severe-bilateral-sars-cov-2-pneumonia-international-journal-of-medical-sciences-4\/\">Post-Intensive Care Unit Multidisciplinary Approach in Patients with Severe Bilateral SARS-CoV-2 Pneumonia &#8211; INTERNATIONAL JOURNAL OF MEDICAL SCIENCES<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Maria Sanchez-Garcia, Ana; Martinez-Lopez, Pilar; Maria Gomez-Gonzalez, Adela; Rodriguez-Capitan, Jorge; Pavon-Moron, Francisco-Javier; Jose Jimenez-Lopez, Rafael; Manuel Garcia-Almeida, Jose; Avanesi-Molina, Elma; Zamboschi, Nicolas; Rueda-Molina, Carolina; Doncel-Abad, Victoria; Isabel Molina-Ramos, Ana; Cabrera-Cesar, Eva; Ben-Abdellatif, Imad; Gordillo-Resina, Marina; Perez-Mesa, Esteban; Nieto-Gonzalez, Maria; Nuevo-Ortega, Pilar; Reina-Artacho, Carmen; Luis Sanchez-Fernandez, Pedro; Francisco Jimenez-Navarro, Manuel; Antonia Estecha-Foncea, Maria &#8211; 2023 &#8211; 10.7150\/ijms.77792<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-37806\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_12 post-37806 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/rectus-femoris-cross-sectional-area-and-phase-angle-aspredictors-of-12-month-mortality-in-idiopathic-pulmonary-fibrosis-patients-nutrients-2\/\">Rectus Femoris Cross-Sectional Area and Phase Angle asPredictors of 12-Month Mortality in Idiopathic Pulmonary Fibrosis Patients &#8211; NUTRIENTS<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Fernandez-Jimenez, Rocio; Cesar, Eva Cabrera; Garcia, Ana Sanchez; Hernandez, Francisco Espildora; Vegas-Aguilar, Isabel M.; Amaya-Campos, Maria del Mar; Cornejo-Pareja, Isabel; Guirado-Pelaez, Patricia; Simon-Frapolli, Victor; Murri, Mora; Garrido-Sanchez, Lourdes; Martinez Mesa, Alvaro; Pinel-Jimenez, Lorena; Gamonoso, Miguel Benitez-Cano; Dalla-Rovere, Lara; Olivares, Maria Garcia; Velasco-Garrido, Jose Luis; Tinahones-Madueno, Francisco; Garcia-Almeida, Jose Manuel &#8211; 2023 &#8211; 10.3390\/nu15204473<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54745\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_13 post-54745 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/bronchial-rupture-secondary-to-placing-a-drainage-archivos-de-bronconeumologia\/\">Bronchial Rupture Secondary to Placing a Drainage &#8211; ARCHIVOS DE BRONCONEUMOLOGIA<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Vera Sanchez, Maria del Carmen; Blanco Diaz, Manuel; Velasco Garrido, Jose Luis &#8211; 2022 &#8211; 10.1016\/j.arbres.2021.02.014<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54750\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_14 post-54750 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/treatment-persistence-and-exacerbations-in-patients-with-asthma-initiating-treatment-with-inhaled-corticosteroids-and-beta-adrenergic-agonists-retrospective-cohort-study-bmj-open\/\">Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study &#8211; BMJ OPEN<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Sicras-Mainar, Antoni; Gomez Rodriguez, Belen; Traseira-Lugilde, Susana; Fernandez-Sanchez, Toni; Luis Velasco Garrido, Jose &#8211; 2022 &#8211; 10.1136\/bmjopen-2021-053964<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54758\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_15 post-54758 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/safety-and-effectiveness-of-abatacept-in-a-prospective-cohort-of-patients-with-rheumatoid-arthritis-associated-interstitial-lung-disease-biomedicines\/\">Safety and Effectiveness of Abatacept in a Prospective Cohort of Patients with Rheumatoid Arthritis-Associated Interstitial Lung Disease &#8211; BIOMEDICINES<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Mena-Vazquez, Natalia; Rojas-Gimenez, Marta; Fuego-Varela, Clara; Garcia-Studer, Aimara; Perez-Gomez, Nair; Maria Romero-Barco, Carmen; Javier Godoy-Navarrete, Francisco; Manrique-Arija, Sara; Gandia-Martinez, Myriam; Calvo-Gutierrez, Jerusalem; Morales-Garrido, Pilar; Mourino-Rodriguez, Coral; Castro-Perez, Patricia; Anon-Onate, Isabel; Espildora, Francisco; Carmen Aguilar-Hurtado, Maria; Hidalgo Conde, Ana; Diez de los Rios, Rocio Arnedo; Cabrera Cesar, Eva; Redondo-Rodriguez, Rocio; Luisa Velloso-Feijoo, Maria; Fernandez-Nebro, Antonio &#8211; 2022 &#8211; 10.3390\/biomedicines10071480<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54761\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_16 post-54761 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/efficacy-and-safety-of-rituximab-in-autoimmune-disease-associated-interstitial-lung-disease-a-prospective-cohort-study-journal-of-clinical-medicine\/\">Efficacy and Safety of Rituximab in Autoimmune Disease-Associated Interstitial Lung Disease: A Prospective Cohort Study &#8211; JOURNAL OF CLINICAL MEDICINE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Mena-Vazquez, Natalia; Redondo-Rodriguez, Rocio; Rojas-Gimenez, Marta; Romero-Barco, Carmen Maria; Manrique-Arija, Sara; Ortega-Castro, Rafaela; Hidalgo Conde, Ana; Arnedo Diez de los Rios, Rocio; Cabrera Cesar, Eva; Espildora, Francisco; Aguilar-Hurtado, Maria Carmen; Anon-Onate, Isabel; Perez-Albaladejo, Lorena; Abarca-Costalago, Manuel; Urena-Garnica, Inmaculada; Velloso-Feijoo, Maria Luisa; Irigoyen-Oyarzabal, Maria Victoria; Fernandez-Nebro, Antonio &#8211; 2022 &#8211; 10.3390\/jcm11040927<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54762\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_17 post-54762 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/importance-of-vaccination-against-sars-cov-2-in-patients-with-interstitial-lung-disease-associated-with-systemic-autoimmune-disease-journal-of-clinical-medicine\/\">Importance of Vaccination against SARS-CoV-2 in Patients with Interstitial Lung Disease Associated with Systemic Autoimmune Disease &#8211; JOURNAL OF CLINICAL MEDICINE<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Mena-Vazquez, Natalia; Garcia-Studer, Aimara; Rojas-Gimenez, Marta; Romero-Barco, Carmen Maria; Manrique-Arija, Sara; Mucientes, Arkaitz; Velloso-Feijoo, Maria Luisa; Godoy-Navarrete, Francisco Javier; Morales-Garrido, Pilar; Redondo-Rodriguez, Rocio; Ordonez-Canizares, M. C.; Ortega-Castro, Rafaela; Lisbona-Montanez, Jose Manuel; Hidalgo Conde, Ana; Arnedo Diez de los Rios, Rocio; Cabrera Cesar, Eva; Espildora, Francisco; Aguilar-Hurtado, Maria Carmen; Anon-Onate, Isabel; Urena-Garnica, Inmaculada; Fernandez-Nebro, Antonio &#8211; 2022 &#8211; 10.3390\/jcm11092437<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54757\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_18 post-54757 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/acute-lung-injury-biomarkers-in-the-prediction-of-covid-19-severity-total-thiol-ferritin-and-lactate-dehydrogenase-antioxidants\/\">Acute Lung Injury Biomarkers in the Prediction of COVID-19 Severity: Total Thiol, Ferritin and Lactate Dehydrogenase &#8211; ANTIOXIDANTS<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Martinez Mesa, Alvaro; Cabrera Cesar, Eva; Martin-Montanez, Elisa; Sanchez Alvarez, Esther; Martinez Lopez, Pilar; Romero-Zerbo, Yanina; Garcia-Fernandez, Maria; Velasco Garrido, Jose Luis &#8211; 2021 &#8211; 10.3390\/antiox10081221<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t\n\t\t\t<article id=\"post-54759\" class=\"et_pb_post clearfix et_pb_no_thumb et_pb_blog_item_2_19 post-54759 post type-post status-publish format-standard hentry category-publicaciones-de-11\">\n\n\t\t\t\t\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t<h2 class=\"entry-title\">\n\t\t\t\t\t\t\t\t\t\t\t\t\t<a href=\"https:\/\/ibima.eu\/en\/characteristics-and-predictors-of-progression-interstitial-lung-disease-in-rheumatoid-arthritis-compared-with-other-autoimmune-disease-a-retrospective-cohort-study-diagnostics\/\">Characteristics and Predictors of Progression Interstitial Lung Disease in Rheumatoid Arthritis Compared with Other Autoimmune Disease: A Retrospective Cohort Study &#8211; DIAGNOSTICS<\/a>\n\t\t\t\t\t\t\t\t\t\t\t<\/h2>\n\t\t\t\t\n\t\t\t\t\t<div class=\"post-content\"><div class=\"post-content-inner et_pb_blog_show_content\"><p>Mena-Vazquez, Natalia; Rojas-Gimenez, Marta; Romero-Barco, Carmen Maria; Manrique-Arija, Sara; Hidalgo Conde, Ana; Arnedo Diez de los Rios, Rocio; Cabrera Cesar, Eva; Ortega-Castro, Rafaela; Espildora, Francisco; Aguilar-Hurtado, Maria Carmen; Anon-Onate, Isabel; Perez-Albaladejo, Lorena; Abarca-Costalago, Manuel; Urena-Garnica, Inmaculada; Velloso-Feijoo, Maria Luisa; Redondo-Rodriguez, Rocio; Fernandez-Nebro, Antonio &#8211; 2021 &#8211; 10.3390\/diagnostics11101794<\/p>\n<\/div><\/div>\t\t\t\n\t\t\t<\/article>\n\t\t\t\t<\/div><div><div class=\"pagination clearfix\">\n\t<div class=\"alignleft\"><a href=\"https:\/\/ibima.eu\/wp-json\/wp\/v2\/project\/54221\/page\/2\/?et_blog\" >&laquo; Older Entries<\/a><\/div>\n\t<div class=\"alignright\"><\/div>\n<\/div><\/div><\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t\t \n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div><div class=\"et_pb_section et_pb_section_7 et_section_regular\" >\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_row et_pb_row_3\">\n\t\t\t\t<div class=\"et_pb_column et_pb_column_4_4 et_pb_column_3  et_pb_css_mix_blend_mode_passthrough et-last-child\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module et_pb_blog_3 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix\">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"entry\">\n\t<h2 class=\"not-found-title\">No Results Found<\/h2>\n\t<p>The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.<\/p>\n<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div> \n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div><div class=\"et_pb_section et_pb_section_9 et_section_regular\" >\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_row et_pb_row_4\">\n\t\t\t\t<div class=\"et_pb_column et_pb_column_4_4 et_pb_column_4  et_pb_css_mix_blend_mode_passthrough et-last-child\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module et_pb_blog_4 et_pb_blog_grid_wrapper et_pb_bg_layout_light\">\n\t\t\t\t\t<div class=\"et_pb_blog_grid clearfix\">\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t\n\t\t\t\t\t<div class=\"et_pb_ajax_pagination_container\">\n\t\t\t\t\t\t<div class=\"entry\">\n\t<h2 class=\"not-found-title\">No Results Found<\/h2>\n\t<p>The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.<\/p>\n<\/div>\n\n\t\t\t\t\t<\/div>\n\t\t\t\t\t<\/div> \n\t\t\t\t<\/div>\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div>\n\t\t\t\t\n\t\t\t\t\n\t\t\t<\/div><div class=\"et_pb_module dsm_icon_list dsm_icon_list_0\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module_inner\">\n\t\t\t\t\t<ul class=\"dsm_icon_list_items dsm_icon_list_ltr_direction dsm_icon_list_layout_vertical\"><\/ul>\n\t\t\t\t<\/div>\n\t\t\t<\/div><div class=\"et_pb_module dsm_icon_list dsm_icon_list_1\">\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t\n\t\t\t\t<div class=\"et_pb_module_inner\">\n\t\t\t\t\t<ul class=\"dsm_icon_list_items dsm_icon_list_ltr_direction dsm_icon_list_layout_vertical\"><\/ul>\n\t\t\t\t<\/div>\n\t\t\t<\/div><\/p>","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"_acf_changed":false,"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[],"project_tag":[],"class_list":["post-54221","project","type-project","status-publish","hentry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>DE-11 - Ibima<\/title>\n<meta name=\"description\" content=\"El grupo emergente de investigaci\u00f3n DE-11 se dedica a investigar todo lo relacionado con la neumolog\u00eda desde M\u00e1laga\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ibima.eu\/en\/project\/de-11\/\" \/>\n<meta property=\"og:locale\" content=\"en_GB\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DE-11 - Ibima\" \/>\n<meta property=\"og:description\" content=\"El grupo emergente de investigaci\u00f3n DE-11 se dedica a investigar todo lo relacionado con la neumolog\u00eda desde M\u00e1laga\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ibima.eu\/en\/project\/de-11\/\" \/>\n<meta property=\"og:site_name\" content=\"Ibima\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-25T12:56:22+00:00\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Estimated reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"13 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/project\\\/de-11\\\/\",\"url\":\"https:\\\/\\\/ibima.eu\\\/project\\\/de-11\\\/\",\"name\":\"DE-11 - Ibima\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\"},\"datePublished\":\"2025-07-30T10:52:17+00:00\",\"dateModified\":\"2025-11-25T12:56:22+00:00\",\"description\":\"El grupo emergente de investigaci\u00f3n DE-11 se dedica a investigar todo lo relacionado con la neumolog\u00eda desde M\u00e1laga\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/ibima.eu\\\/project\\\/de-11\\\/#breadcrumb\"},\"inLanguage\":\"en-GB\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/ibima.eu\\\/project\\\/de-11\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/project\\\/de-11\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Proyectos\",\"item\":\"https:\\\/\\\/ibima.eu\\\/es\\\/project\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"DE-11\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/ibima.eu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/ibima.eu\\\/es\\\/\",\"name\":\"Ibima\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/ibima.eu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-GB\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DE-11 - Ibima","description":"El grupo emergente de investigaci\u00f3n DE-11 se dedica a investigar todo lo relacionado con la neumolog\u00eda desde M\u00e1laga","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ibima.eu\/en\/project\/de-11\/","og_locale":"en_GB","og_type":"article","og_title":"DE-11 - Ibima","og_description":"El grupo emergente de investigaci\u00f3n DE-11 se dedica a investigar todo lo relacionado con la neumolog\u00eda desde M\u00e1laga","og_url":"https:\/\/ibima.eu\/en\/project\/de-11\/","og_site_name":"Ibima","article_modified_time":"2025-11-25T12:56:22+00:00","twitter_card":"summary_large_image","twitter_misc":{"Estimated reading time":"13 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/ibima.eu\/project\/de-11\/","url":"https:\/\/ibima.eu\/project\/de-11\/","name":"DE-11 - Ibima","isPartOf":{"@id":"https:\/\/ibima.eu\/es\/#website"},"datePublished":"2025-07-30T10:52:17+00:00","dateModified":"2025-11-25T12:56:22+00:00","description":"El grupo emergente de investigaci\u00f3n DE-11 se dedica a investigar todo lo relacionado con la neumolog\u00eda desde M\u00e1laga","breadcrumb":{"@id":"https:\/\/ibima.eu\/project\/de-11\/#breadcrumb"},"inLanguage":"en-GB","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ibima.eu\/project\/de-11\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/ibima.eu\/project\/de-11\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/ibima.eu\/es\/"},{"@type":"ListItem","position":2,"name":"Proyectos","item":"https:\/\/ibima.eu\/es\/project\/"},{"@type":"ListItem","position":3,"name":"DE-11"}]},{"@type":"WebSite","@id":"https:\/\/ibima.eu\/es\/#website","url":"https:\/\/ibima.eu\/es\/","name":"Ibima","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ibima.eu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-GB"}]}},"_links":{"self":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/54221","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/comments?post=54221"}],"version-history":[{"count":7,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/54221\/revisions"}],"predecessor-version":[{"id":56674,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project\/54221\/revisions\/56674"}],"wp:attachment":[{"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/media?parent=54221"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project_category?post=54221"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/ibima.eu\/en\/wp-json\/wp\/v2\/project_tag?post=54221"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}